Document Detail

The treatment of heart failure: the role of neurohumoral activation.
MedLine Citation:
PMID:  9550589     Owner:  NLM     Status:  MEDLINE    
Neurohumoral activation refers to increased activity of the sympathetic nervous system, renin-angiotensin system, vasopressin and atrial natriuretic peptide. It is now known that neurohumoral activation contributes to the transition from ventricular dysfunction to clinical heart failure, and is an independent predictor of poor prognosis in heart failure. Although the treatment of heart failure has traditionally focused on drugs to improve ventricular function, there is increasing evidence that therapeutic modulation of neurohumoral activation is a key to successful treatment of heart failure. For example, there is mounting evidence that angiotensin converting enzyme inhibitors (the unquestioned cornerstone for treatment of heart failure), beta receptor blockers, digitalis, and endurance exercise training exert their benefit in heart failure in large part through neurohumoral modulation. This observation--discussed in this brief review--highlights the concept that compensatory neurohumoral activation to decreased cardiac function may itself contribute to the development of heart failure and its poor prognosis.
H R Middlekauff; A L Mark
Related Documents :
15792929 - The use of angiotensin-converting enzyme inhibitors in patients undergoing coronary art...
16270479 - Right ventricular dysfunction in advanced heart failure.
25411159 - Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main re...
25234549 - Managing antithrombotic therapy in patients with both atrial fibrillation and coronary ...
16732689 - Diastolic heart failure in the elderly and the potential role of aldosterone antagonists.
7782629 - Congestive heart failure and pulmonary edema for the emergency physician.
15281499 - An unusual cause of left ventricular outflow tract obstruction after mitral valve repair.
635619 - Interesting approaches to the diagnosis of angina pectoris.
24549279 - The influence of matrix (an)isotropy on cardiomyocyte contraction in engineered cardiac...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  Internal medicine (Tokyo, Japan)     Volume:  37     ISSN:  0918-2918     ISO Abbreviation:  Intern. Med.     Publication Date:  1998 Feb 
Date Detail:
Created Date:  1998-06-17     Completed Date:  1998-06-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9204241     Medline TA:  Intern Med     Country:  JAPAN    
Other Details:
Languages:  eng     Pagination:  112-22     Citation Subset:  IM    
UCLA School of Medicine, Department of Medicine, Los Angeles, California 90095, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Clinical Trials as Topic
Digoxin / therapeutic use
Exercise Therapy
Heart Failure / drug therapy*,  physiopathology*,  therapy
Myocardial Infarction / drug therapy,  physiopathology
Neurotransmitter Agents / physiology*
Receptors, Angiotensin / antagonists & inhibitors
Sympathetic Nervous System / drug effects,  physiopathology
Ventricular Dysfunction, Left / drug therapy,  physiopathology
Grant Support
1R29HL56796/HL/NHLBI NIH HHS; 5 P50 HL55006-02/HL/NHLBI NIH HHS; 5 R37 HL24962-18/HL/NHLBI NIH HHS
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Neurotransmitter Agents; 0/Receptors, Angiotensin; 20830-75-5/Digoxin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ethylene glycol poisoning: toxicokinetic and analytical factors affecting laboratory diagnosis.
Next Document:  Relationship among risk factors of atherosclerosis, leukocyte count, and soluble intercellular adhes...